FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPRO	OVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Galson (Last)	Name and Address of Reporting Person* alson Steven K ast) (First) (Middle) 505 EMPEROR BLVD.						2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX] 3. Date of Earliest Transaction (Month/Day/Year) 06/12/2024									of Reporting Per cable) or (give title		son(s) to Issi 10% Ow Other (s below)	ner	
SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person						
(Street) DURHA	•					Form filed by More than C Person												one Repor	ting	
(City) (State) (Zip)					R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - Nor	n-Deriv	vativ	e Se	curities	s Ac	quired,	Dis	posed o	f, or Be	neficia	lly	Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Da			Code (Instr.					and Securitie Beneficia		es Formally (D) (Following (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o (D)	r Price		Transact (Instr. 3 a	ion(s)			.msu. 4)	
Common Stock 06/12/2							/2024		A		6,820	(1) A	\$0	\$0		36,431(2)		D		
Common Stock															21,9	40(2)		I	By Trust	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		S	. Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisab		expiration Date	Title	Amoun or Numbe of Shares							
Automatic Stock Option Grant ⁽³⁾	\$6.3	06/12/2024			A		49,933		06/12/202	5 0	06/12/2034	Common Stock	49,93	3	\$0	49,933	3	D		

Explanation of Responses:

- 1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
- 2. The shares purchased by the reporting person on May 13, 2024 were inadvertently reported as being purchased directly by the reporting person but were actually purchased by the reporting person's trust. The reporting person is a trustee of such trust and the reporting person and members of his family are the sole beneficiaries of the trust. The reporting person is an indirect beneficial owner of the shares held by the
- 3. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

/s/ Alane P. Barnes, by power of attorney

06/14/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.